TLR Ligand/agonist Potential therapeutic agents TLR1 Triacylated lipoproteins, lipoteichoic acid, peptidoglycans PAM3CSK4 [93] BCG TLR2 Endogenous DAMPs (HSP, HMGB1, uric acid, fibronectin, ECM proteins) [5] PAM3CSK4 [94–96] BCG [97] HSP60…
43. Banchereau J, Schuler-Thurner B, Palucka AK, Schuler G. Dendritic cells as vectors for therapy. Cell. 2001;106(3):271–4.PubMed 44. Enk AH, Angeloni VL, Udey MC, Katz SI. Inhibition of Langerhans cell…
Approach of immunotherapy Model Reference Alpha-galactosylceramide-pulsed antigen-presenting cells Human [93] Anti-CD3/CD28 monoclonal antibody Human [94] CSC-based vaccination In vivo, in vitro [89, 95] DNA-Hsp65 (a DNA vaccine) Human [96] Epstein-Barr…
Antigen Location Expression in tumor Prevalence (%) Description CEA Cell surface (GPI-linked) Overexpressed 30–100 Glycoprotein, normally expressed only on oncofetal tissues. Functions as cell-adhesion molecule. First tumor antigen to be…
Regimen Disease status n ORR CR Survival Reference R-GEM High-grade B-NHL (elderly: 64–78 years) 7 (1 previously untreated) 71 % 29 % PFS:10 m [344] OS:11 m R-GEMOX Aggressive NHL…
Treatment Disease of EGC No. of enrolled patients Clinical response (CR/PR) Median survival (mos) References Cetuximab + FOLFOX/RT + surgery E, ESCC 41 8/12 17 [43] Cetuximab + cisplatin/docetaxel/RT +…
86. Rao H-L, Chen J-W, Li M, et al. Increased intratumoral neutrophil in colorectal carcinomas correlates closely with malignant phenotype and predicts patients’ adverse prognosis. PLoS One. 2012;7:e30806.PubMedCentralPubMed 87. Algars…
Fig. 7.1 The figure demonstrates the immune environment of HRS cells in HL, as well as the antibodies located on the cell surface which are considered potential targets for immunotherapy…
62. Scursoni AM, Galluzzo L, Camarero S, Pozzo N, Gabri MR, de Acosta CM, et al. Detection and characterization of N-glycosylated gangliosides in Wilms tumor by immunohistochemistry. Pediatr Dev Pathol….
Stage Immune phenotype Target Early precursor HLA-DR, TdT, cCD22, CD79a, CD19 CD19 Blinatumomab Intermediate precursor (common) HLA-DR, TdT, cCD22, CD79a, CD19, CD10, CD20 (variable) CD19 Blinatumomab CD20 Rituximab, ofatumumab Late…
